David A. Siegel Prelude Therapeutics Inc Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 225,000 shares of PRLD stock, worth $290,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
225,000
Previous 260,400
13.59%
Holding current value
$290,250
Previous $200,000
9.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PRLD
# of Institutions
50Shares Held
27.9MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$14.1 Million0.32% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$13.1 Million0.08% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA933KShares$1.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD928KShares$1.2 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $46.9M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...